This project entitled "Preclinical Validation of LIMK Inhibitors in Cancer" will receive specific financial support. It is led by Hélène Benedetti, a researcher at the Center for Molecular Biophysics (CBM), and Sylvain Routier, a researcher at the Institute of Organic and Analytical Chemistry (ICOA). Its goal is to determine the efficacy of inhibitors, protein kinases LIMKs, new therapeutic targets particularly interesting to treat cancers for which existing therapies are ineffective. Prematuration will make it possible to characterize the cellular effect of these compounds and to determine their pharmacokinetic properties with a view to performing in vivo tests on three cancer models.
A CBM project is among the winners of the third wave of 2019 CNRS premature program.
06 December 2019 par Isabelle Frapart
05 December 2019 par Isabelle Frapart
07 November 2019 par Isabelle Frapart